Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Pediatric Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03997786Phase 3Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of tildrakizumab in psoriasis, sponsored by Sun Pharma. Started Jan 2020; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03997786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997786.